drugset / Trial / NCT01157988
90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma
Phase 2
Completed
20 enrolled
Chonnam National University Hospital
Asan Medical Center · collabChonbuk National University Hospital · collabDong-A University Hospital · collabPusan National University Hospital · collabSamsung Medical Center · collabSeverance Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II study is aimed at the clinical efficacy and toxicity of 6th R-CHOP chemotherapy followed by ibritumomab tiuxetan (Zevalin) consolidation in patients with limited-stage, bulky diffuse large B cell lymphoma (DLBCL).
Timeline
- Start
- 2007-01
- Primary completion
- 2009-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 11.1 mbq/kg | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 14.8 mbq/kg | Intravenous |
| Background | Rituximab | Monoclonal antibody | 250 mg/m2 | — |